Clinical trial · Observational
Collecting Stem Cells in Patients With Waldenstrom's Macroglobulinemia
Autologous Stem Cell Harvesting for Waldenstrom's Macroglobulinemia
NCT00899119CI-TRIAL-00013082unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Collecting and storing stem cells to study in the laboratory may help doctors learn more about collecting stem cells from patients who have undergone treatment for Waldenstrom's macroglobulinemia. PURPOSE: This laboratory study is collecting stem cells from patients with Waldenstrom's macroglobulinemia.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| leukapheresis | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Number of days to adequate stem cell harvest
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Diagnosis of Waldenstrom's macroglobulinemia (WM) * Less than 30% lymphoplasmacytoid cells in bone marrow by histopathology * Received prior chemotherapy for WM PATIENT CHARACTERISTICS: * ECOG performance status 0-1 * WBC \> 2,000/mm³ * Platelet count \> 50,000/mm³ * LVEF ≥ 50% * No organ dysfunction that would preclude future transplantation PRIOR CONCURRENT THERAPY: * See Disease Characteristics
References
Publications (0)
Data not yet available
No reference posted for this study.